vs
Side-by-side financial comparison of AdvanSix Inc. (ASIX) and Bio-Techne (TECH). Click either name above to swap in a different company.
AdvanSix Inc. is the larger business by last-quarter revenue ($359.9M vs $295.9M, roughly 1.2× Bio-Techne). Bio-Techne runs the higher net margin — 12.8% vs -0.8%, a 13.6% gap on every dollar of revenue. On growth, AdvanSix Inc. posted the faster year-over-year revenue change (9.4% vs -6.4%). Over the past eight quarters, Bio-Techne's revenue compounded faster (4.2% CAGR vs 3.4%).
AdvanSix Inc. is an American chemical company that produces nylon 6 and related chemicals such as caprolactam and ammonium sulfate fertilizers. It operated as Honeywell's Resins and Chemicals division until 2016, when it was spun off as a separate company. The unit accounted for 3 percent of Honeywell's sales at the time. For 2019, revenue is estimated at $1.4 billion. The company traces its lineage to the H. W. Jayne Company, established 1884 in Frankford, Pennsylvania.
Bio-Techne Corporation is an American life sciences company that develops, manufactures and sells life science reagents, instruments and services for the research, diagnostic, and bioprocessing markets.
ASIX vs TECH — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $359.9M | $295.9M |
| Net Profit | $-2.8M | $38.0M |
| Gross Margin | 7.6% | 64.6% |
| Operating Margin | -0.7% | 18.4% |
| Net Margin | -0.8% | 12.8% |
| Revenue YoY | 9.4% | -6.4% |
| Net Profit YoY | -892.9% | 68.3% |
| EPS (diluted) | $-0.11 | $0.24 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $359.9M | $295.9M | ||
| Q3 25 | $374.5M | — | ||
| Q2 25 | $410.0M | $317.0M | ||
| Q1 25 | $377.8M | $316.2M | ||
| Q4 24 | $329.1M | $297.0M | ||
| Q3 24 | $398.2M | $289.5M | ||
| Q2 24 | $453.5M | $306.1M | ||
| Q1 24 | $336.8M | $303.4M |
| Q4 25 | $-2.8M | $38.0M | ||
| Q3 25 | $-2.6M | — | ||
| Q2 25 | $31.4M | $-17.7M | ||
| Q1 25 | $23.3M | $22.6M | ||
| Q4 24 | $352.0K | $34.9M | ||
| Q3 24 | $22.3M | $33.6M | ||
| Q2 24 | $38.9M | $40.6M | ||
| Q1 24 | $-17.4M | $49.1M |
| Q4 25 | 7.6% | 64.6% | ||
| Q3 25 | 6.8% | — | ||
| Q2 25 | 14.3% | 62.7% | ||
| Q1 25 | 14.2% | 67.9% | ||
| Q4 24 | 3.4% | 65.3% | ||
| Q3 24 | 14.4% | 63.2% | ||
| Q2 24 | 17.9% | 66.4% | ||
| Q1 24 | 0.9% | 67.4% |
| Q4 25 | -0.7% | 18.4% | ||
| Q3 25 | -0.9% | — | ||
| Q2 25 | 7.7% | -7.5% | ||
| Q1 25 | 7.7% | 12.2% | ||
| Q4 24 | -3.9% | 16.0% | ||
| Q3 24 | 7.5% | 13.8% | ||
| Q2 24 | 11.5% | 15.0% | ||
| Q1 24 | -7.0% | 22.1% |
| Q4 25 | -0.8% | 12.8% | ||
| Q3 25 | -0.7% | — | ||
| Q2 25 | 7.7% | -5.6% | ||
| Q1 25 | 6.2% | 7.1% | ||
| Q4 24 | 0.1% | 11.7% | ||
| Q3 24 | 5.6% | 11.6% | ||
| Q2 24 | 8.6% | 13.3% | ||
| Q1 24 | -5.2% | 16.2% |
| Q4 25 | $-0.11 | $0.24 | ||
| Q3 25 | $-0.10 | — | ||
| Q2 25 | $1.15 | $-0.11 | ||
| Q1 25 | $0.86 | $0.14 | ||
| Q4 24 | $0.02 | $0.22 | ||
| Q3 24 | $0.82 | $0.21 | ||
| Q2 24 | $1.43 | $0.26 | ||
| Q1 24 | $-0.65 | $0.31 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $19.8M | $172.9M |
| Total DebtLower is stronger | — | $260.0M |
| Stockholders' EquityBook value | $815.2M | $2.0B |
| Total Assets | $1.7B | $2.5B |
| Debt / EquityLower = less leverage | — | 0.13× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $19.8M | $172.9M | ||
| Q3 25 | $23.7M | — | ||
| Q2 25 | $18.4M | $162.2M | ||
| Q1 25 | $8.3M | $140.7M | ||
| Q4 24 | $19.6M | $177.5M | ||
| Q3 24 | $17.3M | $187.5M | ||
| Q2 24 | $12.1M | $152.9M | ||
| Q1 24 | $20.6M | $145.3M |
| Q4 25 | — | $260.0M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $346.0M | ||
| Q1 25 | — | $330.0M | ||
| Q4 24 | — | $300.0M | ||
| Q3 24 | — | $300.0M | ||
| Q2 24 | — | $319.0M | ||
| Q1 24 | — | $389.0M |
| Q4 25 | $815.2M | $2.0B | ||
| Q3 25 | $818.2M | — | ||
| Q2 25 | $823.7M | $1.9B | ||
| Q1 25 | $794.4M | $2.0B | ||
| Q4 24 | $774.6M | $2.1B | ||
| Q3 24 | $766.4M | $2.1B | ||
| Q2 24 | $746.6M | $2.1B | ||
| Q1 24 | $713.2M | $2.0B |
| Q4 25 | $1.7B | $2.5B | ||
| Q3 25 | $1.7B | — | ||
| Q2 25 | $1.6B | $2.6B | ||
| Q1 25 | $1.6B | $2.6B | ||
| Q4 24 | $1.6B | $2.7B | ||
| Q3 24 | $1.5B | $2.7B | ||
| Q2 24 | $1.5B | $2.7B | ||
| Q1 24 | $1.5B | $2.7B |
| Q4 25 | — | 0.13× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 0.18× | ||
| Q1 25 | — | 0.16× | ||
| Q4 24 | — | 0.14× | ||
| Q3 24 | — | 0.14× | ||
| Q2 24 | — | 0.15× | ||
| Q1 24 | — | 0.19× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $63.7M | — |
| Free Cash FlowOCF − Capex | $36.1M | — |
| FCF MarginFCF / Revenue | 10.0% | — |
| Capex IntensityCapex / Revenue | 7.7% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $6.4M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $63.7M | — | ||
| Q3 25 | $26.6M | — | ||
| Q2 25 | $21.1M | $98.2M | ||
| Q1 25 | $11.4M | $41.1M | ||
| Q4 24 | $64.2M | $84.3M | ||
| Q3 24 | $57.3M | $63.9M | ||
| Q2 24 | $50.2M | $75.5M | ||
| Q1 24 | $-36.2M | $81.0M |
| Q4 25 | $36.1M | — | ||
| Q3 25 | $66.0K | — | ||
| Q2 25 | $-7.2M | $93.3M | ||
| Q1 25 | $-22.6M | $31.0M | ||
| Q4 24 | $29.8M | $77.5M | ||
| Q3 24 | $26.8M | $54.7M | ||
| Q2 24 | $16.7M | $57.5M | ||
| Q1 24 | $-71.6M | $64.5M |
| Q4 25 | 10.0% | — | ||
| Q3 25 | 0.0% | — | ||
| Q2 25 | -1.7% | 29.4% | ||
| Q1 25 | -6.0% | 9.8% | ||
| Q4 24 | 9.1% | 26.1% | ||
| Q3 24 | 6.7% | 18.9% | ||
| Q2 24 | 3.7% | 18.8% | ||
| Q1 24 | -21.3% | 21.3% |
| Q4 25 | 7.7% | — | ||
| Q3 25 | 7.1% | — | ||
| Q2 25 | 6.9% | 1.5% | ||
| Q1 25 | 9.0% | 3.2% | ||
| Q4 24 | 10.4% | 2.3% | ||
| Q3 24 | 7.7% | 3.2% | ||
| Q2 24 | 7.4% | 5.9% | ||
| Q1 24 | 10.5% | 5.4% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 0.67× | — | ||
| Q1 25 | 0.49× | 1.82× | ||
| Q4 24 | 182.29× | 2.42× | ||
| Q3 24 | 2.57× | 1.90× | ||
| Q2 24 | 1.29× | 1.86× | ||
| Q1 24 | — | 1.65× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ASIX
| Plant Nutrients | $140.0M | 39% |
| Chemical Intermediates | $92.8M | 26% |
| Caprolactam | $64.4M | 18% |
| Nylon Resins | $62.8M | 17% |
TECH
| Diagnostics And Spatial Biology | $81.2M | 27% |
| EMEA Excluding UK | $75.4M | 25% |
| Other | $42.4M | 14% |
| Instruments | $29.6M | 10% |
| APAC Excluding Greater China | $22.7M | 8% |
| Services | $22.3M | 8% |
| GB | $13.7M | 5% |
| Royalty | $8.5M | 3% |
